Immuneering Corporation Share Price & Technical Analysis
IMRX · $5.22 (0.00%)
Healthcare / Biotechnology
$5.22
0.00%
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Pha…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
4% return in May, 2% avg return in past 3 year May month.
-9% return in 2026, 61% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -30% | 9% | 10% | -2% | 4% | – | – | – | – | – | – | – | -9% |
| 25 | -14% | -16% | -12% | -20% | 42% | 100% | 3% | 76% | 25% | -1% | 13% | -13% | 183% |
| 24 | -20% | 3% | -52% | -50% | -7% | -7% | -15% | -27% | 108% | -24% | 11% | 5% | -76% |
| 23 | -12% | 20% | 87% | 15% | -29% | 31% | 1% | -12% | -14% | -9% | -7% | 7% | 76% |
| 22 | -41% | -25% | -14% | -30% | -8% | 20% | 20% | -12% | 180% | 3% | -54% | -23% | 17% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Emerging · Neutral
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$327.36M
P/E ratio
—
52W high
$10.08
52W low
$1.10
Volume
4,94,399
Beta
0.36
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Immuneering Corporation share price today?
- Immuneering Corporation (IMRX) last traded around $5.22 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does IMRX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for IMRX. Download the app for real-time alerts.
- How can I analyze Immuneering Corporation stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.